Zoetis Inc. (ZTS): R&D Expense
$698.00M
Year ended 2025-12-31
+9.0%
3-year compound annual growth
+8.6%
5-year compound annual growth
+6.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $698.00M | +1.7% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $686.00M | +11.7% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $614.00M | +13.9% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $539.00M | +6.1% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $508.00M | +9.7% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $463.00M | +1.3% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $457.00M | +5.8% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $432.00M | +13.1% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $382.00M | +1.6% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $376.00M | +3.3% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $364.00M | -8.1% | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | $396.00M | -0.8% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $399.00M | -2.4% | 2016-02-24, From 2013-01-01 |
| 2012-12-31 | $409.00M | -4.2% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $427.00M | n/a | 2014-03-26, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zoetis Inc. (ZTS) | 2025-12-31 | $698.00M | +1.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $629.00M | +2.1% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $3.91B | +7.7% |
| Viatris Inc (VTRS) | 2025-12-31 | $965.90M | +19.4% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $5.85B | +14.0% |
| Organon & Co. (OGN) | 2025-12-31 | $366.00M | -22.0% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $2.15B | +9.9% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.01B | +1.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
Compare ZTS, BHC, VRTX, VTRS side by side · Screen every company in Pharmaceutical Preparations ↗